Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis.
Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV. Kittai AS, et al. Among authors: denlinger n. Transplant Cell Ther. 2021 Jan;27(1):46-52. doi: 10.1016/j.bbmt.2020.09.028. Epub 2020 Sep 29. Transplant Cell Ther. 2021. PMID: 33002640 Free article.
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D. Brammer JE, et al. Among authors: denlinger n. J Immunother Cancer. 2021 Aug;9(8):e002303. doi: 10.1136/jitc-2020-002303. J Immunother Cancer. 2021. PMID: 34429331 Free PMC article.
CAR T-cell therapy for B-cell lymphoma.
Denlinger N, Bond D, Jaglowski S. Denlinger N, et al. Curr Probl Cancer. 2022 Feb;46(1):100826. doi: 10.1016/j.currproblcancer.2021.100826. Epub 2021 Dec 25. Curr Probl Cancer. 2022. PMID: 35012754 Free PMC article. Review.
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
Sigmund AM, Denlinger N, Huang Y, Bond D, Voorhees T, Bajwa A, Elder P, Brammer JE, Saad A, Penza S, Vasu S, de Lima M, Jaglowski S, Kittai AS. Sigmund AM, et al. Among authors: denlinger n. Transplant Cell Ther. 2022 Jun;28(6):342.e1-342.e5. doi: 10.1016/j.jtct.2022.02.021. Epub 2022 Mar 4. Transplant Cell Ther. 2022. PMID: 35248778 Free PMC article.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Zurko J, et al. Among authors: denlinger n. Haematologica. 2023 Jan 1;108(1):98-109. doi: 10.3324/haematol.2022.281242. Haematologica. 2023. PMID: 35833303 Free PMC article.
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R. Zurko J, et al. Among authors: denlinger n. Blood Adv. 2023 Jun 27;7(12):2657-2669. doi: 10.1182/bloodadvances.2022008240. Blood Adv. 2023. PMID: 36094847 Free PMC article.
Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.
Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, Wu D, Chan WK, Bezerra ED, Epperla N, Voorhees TJ, Brammer JE, Kittai AS, Bond DA, Sawalha Y, Sigmund AM, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks KJ, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski SM, Li Z, Huang X, Yang Y. Denlinger N, et al. Blood Adv. 2024 Mar 23:bloodadvances.2023012073. doi: 10.1182/bloodadvances.2023012073. Online ahead of print. Blood Adv. 2024. PMID: 38607381
Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.
Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A. Mundy-Bosse B, et al. Among authors: denlinger n. Blood Adv. 2018 Aug 14;2(15):1818-1827. doi: 10.1182/bloodadvances.2018020388. Blood Adv. 2018. PMID: 30054309 Free PMC article.
18 results